Suvemcitug

DRUG2 trials

Sponsors

Peking University Third Hospital, Fudan University

Conditions

PROCRectal Cancer

Phase 2

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

Not yet recruitingNCT07741630

Peking University Third HospitalPROC

Start: 2026-08-15End: 2028-04-30Target: 20Updated: 2026-08-03

Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer

Not yet recruitingNCT07810114

Fudan UniversityRectal Cancer

Start: 2026-08-28End: 2030-12-01Target: 52Updated: 2026-09-09